1 Big Winner and 1 Loser From the Upcoming Anthropic IPO

Anthropic's upcoming IPO will have divergent impacts on companies in the AI and biotech sectors. Broadcom stands to benefit significantly from a $161.2 billion, five-year non-cancellable agreement to provide AI chip capacity to Anthropic. Conversely, Recursion Pharmaceuticals faces headwinds as Anthropic's Claude AI model becomes a standard tool for drug discovery among major pharmaceutical companies, eroding Recursion's competitive advantage despite the biotech having no approved drugs since its 2013 founding.